Seragon Pharmaceuticals Inc. is picking up where its predecessor Aragon Pharmaceuticals Inc. left off after Johnson & Johnson acquired the company for its androgen receptor antagonists. The Aragon spinout raised $30 million in a series A round last October and is using the funds to develop oral small molecules that both block estrogen receptors and induce their degradation.

The company said it will initially focus on advancing its Selective Estrogen Receptor Degraders (SERDs) program in ER-positive metastatic breast cancer patients who have failed anti-estrogen therapy.